Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lull before Pop?

<< Previous

Bullboard Posts

Next >>

Comment by Pragmatiston Jul 16, 2021 2:48am

202 Views

Post# 33557808

RE:RE:RE:RE:Lull before Pop?

MrMugsy wrote: Ya - I once asked Dan about fast-tracking OTENA (around August of last year).
I think his answer was ... there's no point now.
I didn't challenge further as I moved on to another question.

Which begs the question now ... when is the right time to fast-track 352?
As I understand it ... you can complete the paperwork at any point in the development cycle.

Thoughts ?

mstrmnd wrote: tuah nod

A question that I have been pondering is how much effort do you spend progressing 352 when you have a more promising new candidate close on its heels? I believe Dan stated during Radius (Apr 21) that he would work the two in parallel and hand off at the right time. And that it would be 12-15 mths before it is tested in humans. So when is the right time?

Fast track can be requested as early as IND. I suspect that the timeline will be dependent on Delriada's lab results. Clearly it would be in ATE's interests to down tools on the old molecule and focus on the new molecule at the earliest opportunity. Which would drive the schedule. And which would avoid rework.